In the United States, where 1 in 680 people between 20 and 50 years old are survivors of childhood cancer, the impact of long-term health consequences is a cause for concern, and even more so because this population is increasing.
Data represented May 18, 2015, at the American Urological Association annual meeting in New Orleans, certainly grabbed headlines.
The report found a 6.5% increase in the compound annual growth rate during the 5-year period leading up to 2014.
BMS has submitted phase 3 results from the CheckMate-066 trial, comparing nivolumab with dacarbazine in treatment-naïve advanced melanoma patients.
Evidence-Based Oncology's editor in chief introduces the special issue on cardio-oncology.


May 15-19, 2015
New Orleans, LA
May 29-June 2, 2015
Chicago, IL
June 11-14, 2015
Vienna, Austria
June 17-20, 2015
Lugano, Switzerland